secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2026-06-02T12:04:53+00:00
Accession:  0001437749-26-019102
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030
--------------------------------------------------------------------------------

- Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.
- Teva granted non-exclusive license to sell generic Jelmyto starting September 15, 2030, if FDA approved.
- All ongoing patent litigation between the parties in U.S. District Court for Delaware will be terminated.
- Agreement is subject to review by U.S. Federal Trade Commission and U.S. Department of Justice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/0001437749-26-019102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000143774926019102/urgn20260601_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-019102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer